Serum osteoprotegerin concentration with strontium ranelate treatment for postmenopausal osteoporosis: An open prospective study

Ertorer M. E. , Bakiner O., Anaforoglu I., Sezgin N. , Dernirag N. G. , Tutuncu N. B.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, cilt.68, sa.4, ss.217-225, 2007 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 68 Konu: 4
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1016/j.curtheres.2007.08.001
  • Sayfa Sayıları: ss.217-225


Background: Strontium ranelate (SR) is a new antiosteoporotic agent with antiresorptive and bone-forming properties. The exact mechanism by which SR exerts its effects is not clearly understood. Bone resorption requires interaction between osteoblasts and osteoclasts. Osteoblasts produce a ligand for receptor activator of nuclear factor-kappa B (RANK). They also secrete osteoprotegerin, a decoy protein that blocks the interaction of RANK with its ligand, thereby inhibiting the differentiation and activity of osteoclasts. SR also has been associated with osteoblast proliferation and decreased osteoblast-induced osteoclast differentiation via increased osteoprotegerin messenger RNA expression in human osteoblasts.